Trial · NCT00813943
Results by group61
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 61
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Survival (OS) Time | Cilengitide (2-times Weekly) + Temozolomide + Radiotherapy | 16.3 | 95% Confidence Interval 13.2 to 18.1 | Months | |
| Overall Survival (OS) Time | Cilengitide (5-times Weekly) + Temozolomide + Radiotherapy | 14.5 | 95% Confidence Interval 12.6 to 16.5 | Months | |
| Overall Survival (OS) Time | Temozolomide + Radiotherapy | 13.4 | 95% Confidence Interval 12.2 to 14.3 | Months | |
| Progression Free Survival (PFS) Time - Investigator and Independent Read | Cilengitide (2-times Weekly) + Temozolomide + Radiotherapy | PFS Time: Independent read | 5.6 | 95% Confidence Interval 3.6 to 5.9 | Months |
| Progression Free Survival (PFS) Time - Investigator and Independent Read | Cilengitide (5-times Weekly) + Temozolomide + Radiotherapy | PFS Time: Independent read | 5.9 | 95% Confidence Interval 4.2 to 7.6 | Months |
| Progression Free Survival (PFS) Time - Investigator and Independent Read | Temozolomide + Radiotherapy | PFS Time: Independent read | 4.1 | 95% Confidence Interval 3.7 to 4.7 | Months |
| Progression Free Survival (PFS) Time - Investigator and Independent Read | Cilengitide (2-times Weekly) + Temozolomide + Radiotherapy | PFS Time: Investigator read | 6.4 | 95% Confidence Interval 4.2 to 7.9 | Months |
| Progression Free Survival (PFS) Time - Investigator and Independent Read | Cilengitide (5-times Weekly) + Temozolomide + Radiotherapy | PFS Time: Investigator read | 7.5 | 95% Confidence Interval 5.9 to 8.2 | Months |
| Progression Free Survival (PFS) Time - Investigator and Independent Read | Temozolomide + Radiotherapy | PFS Time: Investigator read | 6.0 | 95% Confidence Interval 4.1 to 7.7 | Months |
| Maximum Observed Plasma Concentration (Cmax) | Cilengitide (5-times Weekly) + Temozolomide + Radiotherapy | Day 1 (Single dose) | 108527 | Standard Deviation 27197 | nanogram per milliliter (ng/mL) |
| Maximum Observed Plasma Concentration (Cmax) | Cilengitide (5-times Weekly) + Temozolomide + Radiotherapy | Day 5 (Repeated doses) | 150873 | Standard Deviation 97220 | nanogram per milliliter (ng/mL) |
| Time to Maximum Plasma Concentration (Tmax) and Terminal Elimination Half-Life (t1/2) | Cilengitide (5-times Weekly) + Temozolomide + Radiotherapy | Tmax: Day 1 (Single dose) | 0.97 | Standard Deviation 0.34 | hours |
| Time to Maximum Plasma Concentration (Tmax) and Terminal Elimination Half-Life (t1/2) | Cilengitide (5-times Weekly) + Temozolomide + Radiotherapy | Tmax: Day 5 (Repeated doses) | 1.17 | Standard Deviation 0.34 | hours |
| Time to Maximum Plasma Concentration (Tmax) and Terminal Elimination Half-Life (t1/2) | Cilengitide (5-times Weekly) + Temozolomide + Radiotherapy | t1/2: Day 1 (Single dose) | 2.38 | Standard Deviation 0.8 | hours |
| Time to Maximum Plasma Concentration (Tmax) and Terminal Elimination Half-Life (t1/2) | Cilengitide (5-times Weekly) + Temozolomide + Radiotherapy | t1/2: Day 5 (Repeated doses) | 2.44 | Standard Deviation 0.8 | hours |
| Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity (AUC [0-infinity]) and Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours (AUC [0-24]) | Cilengitide (5-times Weekly) + Temozolomide + Radiotherapy | AUC (0-infinity): Day 1 (Single dose) | 280944 | Standard Deviation 75720 | hour*ng/mL |
| Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity (AUC [0-infinity]) and Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours (AUC [0-24]) | Cilengitide (5-times Weekly) + Temozolomide + Radiotherapy | AUC (0-infinity): Day 5 (Repeated Doses) | 335263 | Standard Deviation 105435 | hour*ng/mL |
| Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity (AUC [0-infinity]) and Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours (AUC [0-24]) | Cilengitide (5-times Weekly) + Temozolomide + Radiotherapy | AUC (0-24): Day 1 (Single dose) | 269941 | Standard Deviation 82850 | hour*ng/mL |
| Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity (AUC [0-infinity]) and Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours (AUC [0-24]) | Cilengitide (5-times Weekly) + Temozolomide + Radiotherapy | AUC (0-24): Day 5 (Repeated doses) | 316137 | Standard Deviation 110425 | hour*ng/mL |
| Plasma Concentration at Pre-dose (Cpre) and Plasma Concentration at End of Infusion (CT) | Cilengitide (5-times Weekly) + Temozolomide + Radiotherapy | Cpre: Day 1 (Single dose) | 6372.7 | Standard Deviation 21135.95 | ng/mL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00813943/results